Bragar Eagel & Squire, P.C. Reminds James Hardie and Baxter International Investors to Contact the Firm Regarding Their Rights

NEW YORK, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of James Hardie Industries plc (NYSE:JHX) and Baxter International, Inc. (NYSE:BAX). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

James Hardie Industries plc (NYSE:JHX)

Class Period: May 20, 2025 through August 18, 2025
Lead Plaintiff Deadline: December 23, 2025
The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that: (1) James Hardie's key North America Fiber Cement segment was experiencing weakening demand due to distributor inventory destocking known to the Company by April and early May 2025; and (2) despite this knowledge, the Company falsely represented that demand remained strong and that inventory levels were "normal"; and (3) on August 19, 2025, James Hardie revealed a 12% sales decline in the segment, attributing it to "normalization of channel inventories," and warned of continued weakness; and (4) following this news, the Company's share price dropped more than 34% thereby damaging investors.
For more information on the James Hardie lawsuit go to: https://bespc.com/cases/JHX

Baxter International, Inc. (NYSE:BAX)

Class Period: February 23, 2022 to July 30, 2025
Lead Plaintiff Deadline: December 15, 2025
The Complaint alleges that throughout the Class Period, Defendants misled investors by failing to disclose that: (1) the Novum LVP suffered systemic defects that caused widespread malfunctions, including underinfusion, overinfusion, and complete non-delivery of fluids, which exposed patients to risks of serious injury or death; (2) Baxter was notified of multiple device malfunctions, injuries, and deaths from these defects; (3) Baxter's attempts to address these defects through customer alerts were inadequate remedial measures, when design flaws persisted and continued to cause serious harm to patients; (4) as a result, there was a heightened risk that customers would be instructed to take existing Novum LVPs out of service and that Baxter would completely pause all new sales of these pumps; and (5) based on the foregoing, Baxter's statements about the safety, efficacy, product rollout, customer feedback and sales prospects of the Novum LVPs were materially false and misleading.
For more information on the Baxter lawsuit go to: https://bespc.com/cases/BAX

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X.

Contact Information:

Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.